TY  - INPR
A1  - Wilhelm, Alexander
A1  - Widera, Marek
A1  - Grikscheit, Katharina
A1  - Toptan, Tuna
A1  - Schenk, Barbara
A1  - Pallas, Christiane
A1  - Metzler, Melinda
A1  - Kohmer, Niko
A1  - Hoehl, Sebastian
A1  - Helfritz, Fabian Arnold
A1  - Wolf, Timo
A1  - Götsch, Udo
A1  - Ciesek, Sandra
T1  - Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
T2  - medRxiv
N2  - Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/73637
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-736371
UR  - https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v1
IS  - 2021.12.07.21267432 Version 1
ER  -